Below are the top 10 Biotechnology stocks with highest Return on Equity (ROE) ratio for the last 12 months. ROE shows a company's efficiency in making profits from shareholders' equity. It is equal to net profits divided by shareholders' equity. One Chinese company (CPHI) is on the list.
Immunomedics, Inc. (NASDAQ:IMMU) has the 1st highest Return on Equity in this segment of the market. Its ROE was 183.92% for the last 12 months. Its net profit margin was 58.79% for the same period. CARDIOME PHARMA CORP (NASDAQ:CRME) has the 2nd highest Return on Equity in this segment of the market. Its ROE was 136.97% for the last 12 months. Its net profit margin was 34.35% for the same period. Talecris Biotherapeutics Holdings Corp (NASDAQ:TLCR) has the 3rd highest Return on Equity in this segment of the market. Its ROE was 101.84% for the last 12 months. Its net profit margin was 17.85% for the same period. Gilead Sciences, Inc. (NASDAQ:GILD) has the 4th highest Return on Equity in this segment of the market. Its ROE was 51.77% for the last 12 months. Its net profit margin was 38.63% for the same period. Keryx Biopharmaceuticals (NASDAQ:KERX) has the 5th highest Return on Equity in this segment of the market. Its ROE was 42.86% for the last 12 months. Its net profit margin was 27.53% for the same period.
GTx, Inc. (NASDAQ:GTXI) has the 6th highest Return on Equity in this segment of the market. Its ROE was 31.73% for the last 12 months. Its net profit margin was 13.87% for the same period. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has the 7th highest Return on Equity in this segment of the market. Its ROE was 31.01% for the last 12 months. Its net profit margin was 21.30% for the same period. Palatin Technologies, Inc. (AMEX:PTN) has the 8th highest Return on Equity in this segment of the market. Its ROE was 30.48% for the last 12 months. Its net profit margin was 12.65% for the same period. Genentech, Inc. (NYSE:DNA) has the 9th highest Return on Equity in this segment of the market. Its ROE was 24.85% for the last 12 months. Its net profit margin was 25.54% for the same period. China Pharma Holdings, Inc. (AMEX:CPHI) has the 10th highest Return on Equity in this segment of the market. Its ROE was 24.39% for the last 12 months. Its net profit margin was 32.68% for the same period.
source:cnanalyst
No comments:
Post a Comment